Clinical Trials Directory

Trials / Completed

CompletedNCT00758160

The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

From Immediate-release MPH to OROS MPH: The Impact Upon Family of Children and Adolescents With ADHD

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
296 (actual)
Sponsor
Johnson & Johnson Taiwan Ltd · Industry
Sex
All
Age
6 Years – 18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate whether familial relationships and psychological status of participants or caregivers as well as Attention Deficit Hyperactivity Disorder (ADHD) symptoms of participants can be improved by switching from Immediate-release Methylphenidate (IR-MPH) to Osmotic Release Oral Delivery System Methylphenidate (OROS-MPH).

Detailed description

This is a prospective (study following participants forward in time), single-arm, open-label (all people know the identity of the intervention), 8-week, multi-centric (conducted in more than 1 center) study. OROS-MPH will be administered orally for 2 months at doses of 18, 36, or 54 milligram (mg) to replace IR-MPH. Clinicians will adjust the dose of each participant according to participant's clinical responses and/or side effects. During the study period, participants will be assessed on Week 2, 4, and 8. Efficacy will be evaluated primarily based on change from baseline in Chinese version of the 26-item Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) rating scale assessed by parents and Chinese Health Questionnaire (CHQ). Safety will be monitored throughout the study.

Conditions

Interventions

TypeNameDescription
DRUGOROS MethylphenidateParticipants will receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.

Timeline

Start date
2008-03-01
Primary completion
2008-06-01
Completion
2008-06-01
First posted
2008-09-23
Last updated
2014-04-08
Results posted
2014-04-08

Source: ClinicalTrials.gov record NCT00758160. Inclusion in this directory is not an endorsement.